Efficacy of continuous subcutaneous infusion therapy using interferon alpha and the possible prognostic indicator of TNF-alpha in renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  International journal of urology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9354944
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-α

  2005cited by this paper
• Modulation of immune parameters in patients with metastatic renal‐cell cancer receiving combination immunotherapy (IL‐2, IFNα and autologous IL‐2‐activated lymphocytes)

  1996cited by this paper
• Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 andα-IFN

  1995cited by this paper
• Evaluation of Low Dose Alpha-Interferon (Roferon-A®) in Patients with Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study

  1995cited by this paper
• [Continuous subcutaneous injection therapy with interferon-alpha for renal cell carcinoma patients with bone metastasis].

  1995cited by this paper
• Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization.

  1994cited by this paper
• Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2.

  1994cited by this paper
• Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha.

  1994cited by this paper
• Direct and indirect effects of human interferon α on renal cell carcinoma: a new in vitro assay system for evaluating cytokine-mediated antitumor effects

  1993cited by this paper
• The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.

  1991cited by this paper
• In vitro production of human interleukin 1 alpha and interleukin 1 beta by peripheral blood mononuclear cells examined by sensitive sandwich enzyme immunoassay.

  1987cited by this paper
• A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.

  1985cited by this paper
• The natural history of renal carcinoma.

  1983cited by this paper

• Multi‐modal treatment of primarily using continuous subcutaneous interferon‐α injection in combination with surgery and/or radiotherapy

  2005cites this paper
• Sleep in host defense.

  2003cites this paper
• Pharmacokinetics of natural human IFN-alpha in hemodialysis patients.

  1999cites this paper